LumiThera’s PBM is the only device that has demonstrated meaningful vision improvement compared to baseline for people living ...

Alcon to Acquire LumiThera and its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD) ...

Alcon has inked a deal to acquire LumiThera and its light-based therapy for dry age-related macular degeneration, which obtained a groundbreaking FDA clearance late last year. | LumiThera's approach ...

Sean Clark, the VP and general manager of Alcon’s Global Surgical Franchise, added: “Dry AMD is an area of significant unmet ...

HOUSTON, TX / ACCESS Newswire / July 9, 2025 / Mann Eye Institute, a leader in innovative eye care since the 1970s, is proud ...

LumiThera Inc., a medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced the topline results from the LIGHTSITE IIIB Extension Trial, a ...

LumiThera wants patients to have access to non-invasive Valeda treatments to improve vision and address the disease earlier in the process,” stated Clark Tedford, Ph.D., LumiThera President and CEO.

LumiThera’s Valeda became the first non-invasive approach for treating dry AMD following its authorisation by the US Food and Drug Administration (FDA) in November 2024.

This is a developing news story. Please check back soon for updates. Alcon will acquire LumiThera, including its ...

LumiThera’s photobiomodulation (PBM) device is the first and only technology that has demonstrated meaningful visual improvement with two years of treatments* in early and intermediate dry AMD ...

LumiThera’s photobiomodulation (PBM) device is the first and only technology that has demonstrated meaningful visual improvement with two years of treatments* in early and intermediate dry AMD ...

Monday announced its intention to acquire LumiThera and its PBM device for the treatment of early and intermediate dry AMD.